Through this approval, eculizumab becomes a first anti-complement medical therapy indicated for treating two rare conditions- paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic ...

Voydeya (danicopan) can now be used as add-on therapy to AZ’s complement C5 inhibitors Ultomiris (ravulizumab) or Soliris (eculizumab) to treat extravascular haemolysis (EVH) in adults with PNH ...

A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the ...

See full prescribing information for complete boxed warning. Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meningitidis. Life-threatening ...

Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway ... with PNH who were switched from anti-C5 therapies (eculizumab or ravulizumab). Year to date, shares of Novartis ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

One significant area of research has been the evaluation of treatments targeting the complement system, particularly the C5 inhibitors eculizumab and ravulizumab. A survey of PNH patients ...

EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS ...

Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meningitidis. Life-threatening and fatal meningococcal infections have occurred in patients ...

See full prescribing information for complete boxed warning. Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meningitidis. Life-threatening and ...